Suboxone Treatment: How It Works and What to Know

Key Takeaways

• Suboxone is a brand-name medication containing buprenorphine and naloxone (Narcan), prescribed for the treatment of opioid use disorder (OUD) including addiction to heroin, fentanyl, and prescription painkillers.
• Buprenorphine is a partial opioid agonist with a ceiling effect, meaning it reduces cravings and withdrawal without producing the full euphoria of other opioids and has a lower overdose risk.
• Suboxone treatment involves three phases: induction (starting the medication), stabilization (finding the right dose), and maintenance (long-term treatment).
• NIDA and SAMHSA support long-term Suboxone maintenance, as ongoing treatment produces significantly better outcomes than short-term use followed by taper.
• NJ Medicaid covers Suboxone and other buprenorphine formulations, and the X-waiver prescribing requirement was eliminated in 2023, expanding provider access.
• Telehealth Suboxone treatment has become widely available since the COVID-19 pandemic, though patients should verify provider legitimacy.

Suboxone is one of the most widely prescribed medications for opioid use disorder in the United States, and for good reason — it has a strong evidence base, a favorable safety profile, and can be prescribed in standard medical offices rather than requiring specialized clinics. Despite its widespread use, many individuals and families still have questions about what Suboxone is, how it works, what treatment involves, and how to access it affordably.

This page provides a comprehensive, evidence-based overview of Suboxone treatment for opioid addiction, including what to expect during treatment and how to find providers in New Jersey.

What Is Suboxone and How Does It Work

Buprenorphine and Naloxone Explained

Suboxone contains two active ingredients, each with a distinct pharmacological role:

Buprenorphine is a partial mu-opioid agonist. This means it binds to the same opioid receptors as heroin, fentanyl, and prescription painkillers, but activates them only partially. The practical effect:

• Reduces withdrawal symptoms by providing enough opioid receptor stimulation to prevent the autonomic nervous system rebound that causes withdrawal
• Reduces cravings by occupying opioid receptors and modestly stimulating the reward pathway
• Has a ceiling effect — beyond a certain dose (approximately 24-32 mg), increasing the dose does not increase the opioid effect. This ceiling dramatically reduces the risk of respiratory depression and overdose compared to full agonists like heroin, fentanyl, or methadone (Dolophine/Methadose).
• Has high receptor binding affinity — once buprenorphine occupies the receptors, it is difficult for other opioids to displace it. This means that using heroin or fentanyl while on an adequate dose of buprenorphine produces little to no euphoria.

Naloxone (Narcan) is an opioid antagonist included in Suboxone as an abuse deterrent. When Suboxone is taken sublingually (under the tongue) as prescribed, naloxone has minimal bioavailability — it is poorly absorbed through the oral mucosa and has little clinical effect. However, if Suboxone is dissolved and injected, the naloxone becomes fully bioavailable and can precipitate immediate withdrawal, discouraging misuse by injection.

How Suboxone Reduces Cravings and Withdrawal

The mechanism through which buprenorphine (Suboxone/Sublocade) manages opioid use disorder operates on multiple levels:

1. Receptor occupation: By occupying mu-opioid receptors, buprenorphine prevents them from being activated by other opioids. This reduces the rewarding effects of using heroin or fentanyl, removing the primary reinforcement for drug-seeking behavior.

2. Withdrawal prevention: Partial agonist activity provides enough receptor stimulation to prevent the noradrenergic storm that causes withdrawal symptoms. Patients stabilized on Suboxone do not experience the cycles of intoxication and withdrawal that characterize active opioid use disorder.

3. Craving reduction: The steady-state receptor occupation provided by daily buprenorphine dosing normalizes brain reward circuitry over time, progressively reducing the intensity of drug cravings.

4. Long half-life: Buprenorphine has a half-life of approximately 24 to 42 hours, allowing once-daily dosing and preventing the frequent highs and lows associated with short-acting opioid use.

What Suboxone Treatment Looks Like

Induction Phase

Induction is the process of starting Suboxone treatment. This phase requires careful timing:

• Waiting period: The patient must be in at least mild to moderate opioid withdrawal before the first dose. For short-acting opioids (heroin, fentanyl), this typically means waiting 12 to 24 hours after last use. The Clinical Opiate Withdrawal Scale (COWS) score should reach at least 12 before induction begins.
• Fentanyl considerations: Patients transitioning from fentanyl face a higher risk of precipitated withdrawal during standard induction because fentanyl can persist in fatty tissue. Many providers now use micro-dosing (Bernese method) protocols — starting with very small buprenorphine doses while the patient is still using opioids, then gradually increasing — to avoid this complication.
• First-day dosing: A typical first-day dose ranges from 2 to 8 mg of buprenorphine, with additional doses as needed based on symptom response.
• Setting: Induction can occur in a physician’s office, outpatient clinic, emergency department, or inpatient facility. Some patients complete home induction with provider guidance.

Stabilization and Maintenance

After successful induction, treatment enters the stabilization phase:

• Dose optimization: Over the first 1 to 2 weeks, the dose is adjusted until withdrawal symptoms and cravings are adequately controlled. Most patients stabilize on 8 to 16 mg/day, though fentanyl-dependent individuals may require 16 to 24 mg/day.
• Visit frequency: Initially, patients may see their provider weekly. As stability is established, visit intervals extend to biweekly, then monthly.
• Urine drug screening: Regular drug testing confirms medication adherence and monitors for continued substance use. Positive results are treated as clinical information, not grounds for discharge.
• Behavioral therapy: SAMHSA recommends that behavioral counseling accompany MAT, though access to Suboxone should not be contingent on counseling attendance.

The maintenance phase — ongoing Suboxone treatment — has no predefined endpoint. Current evidence supports continuation as long as the medication provides clinical benefit.

Tapering Off Suboxone

The question of when and whether to taper off Suboxone is complex and should be individualized:

• Evidence favors longer treatment: Studies consistently show that patients who remain on buprenorphine maintenance have lower relapse rates, fewer overdose events, and better quality of life than those who taper off.
• Taper is not required: NIDA, SAMHSA, and ASAM all affirm that long-term or indefinite maintenance is a legitimate and evidence-supported treatment approach. There is no medical requirement to taper.
• When taper is considered: Some individuals, after a year or more of stable recovery, wish to discontinue medication. Gradual tapering (over months, not weeks) under medical supervision gives the best chance of success.
• Taper risks: Relapse rates increase significantly after buprenorphine discontinuation, particularly in the first 1 to 3 months. Overdose risk increases if relapse occurs because tolerance has decreased.

Benefits and Limitations of Suboxone

Evidence for Effectiveness

The clinical evidence for buprenorphine (Suboxone/Sublocade) in treating opioid use disorder is extensive:

• Treatment retention: Buprenorphine maintenance significantly improves treatment retention compared to detox alone or behavioral therapy alone
• Overdose reduction: Patients on buprenorphine maintenance have substantially lower rates of fatal overdose
• Reduced illicit opioid use: Randomized controlled trials demonstrate significant reductions in heroin and other opioid use during buprenorphine treatment
• Improved social functioning: Employment, housing stability, and family relationships improve during stable treatment
• Reduced criminal activity: Individuals in MAT programs show lower rates of drug-related criminal behavior
• Reduced disease transmission: By reducing injection drug use, MAT decreases the spread of HIV and hepatitis C

Common Side Effects and Concerns

Like all medications, buprenorphine has side effects and limitations:

Common side effects:

• Constipation (the most frequently reported)
• Headache
• Nausea (usually transient during induction)
• Sweating
• Insomnia or drowsiness
• Mouth numbness from sublingual administration

Common concerns addressed:

• “Is Suboxone trading one addiction for another?” This is the most common misconception about MAT. Buprenorphine produces physical dependence (stopping it causes withdrawal), but dependence is not the same as addiction. Individuals stabilized on Suboxone function normally — they work, parent, drive, and live without impairment. The distinction between managed medication dependence and active addiction is clinically and practically significant.
• Diversion potential: While buprenorphine diversion exists, research shows that the majority of diverted Suboxone is used for self-treatment of withdrawal rather than to get high. The extended-release injection formulation (Sublocade) eliminates diversion risk entirely.
• Dental issues: The FDA has identified a risk of dental problems (cavities, oral infections) associated with sublingual buprenorphine formulations. Regular dental care is recommended for patients on Suboxone.

Accessing Suboxone Treatment in New Jersey

Finding a Suboxone Provider in NJ

The landscape for accessing buprenorphine treatment has improved significantly:

• X-waiver elimination (2023): As of January 2023, the federal requirement for a special DEA waiver (X-waiver) to prescribe buprenorphine has been eliminated. Any physician, nurse practitioner, or physician assistant with a DEA license can now prescribe buprenorphine for opioid use disorder. This policy change has the potential to dramatically expand provider availability.
• SAMHSA Provider Locator: The SAMHSA treatment locator (findtreatment.gov) allows searches for buprenorphine prescribers by location.
• NJ DMHAS: The Division of Mental Health and Addiction Services maintains information on licensed treatment programs throughout New Jersey.
• Federally Qualified Health Centers (FQHCs): Many NJ FQHCs integrate buprenorphine prescribing into primary care, making treatment accessible in the same setting as general medical care.
• NJ Substance Abuse Hotline (1-844-276-2777): Provides referrals to Suboxone providers across the state.

Low-Cost and Insurance Options

Cost should not be a barrier to Suboxone treatment in New Jersey:

• NJ Medicaid: Covers buprenorphine in all formulations (Suboxone film/tablet, Sublocade injection, generic buprenorphine/naloxone). NJ Medicaid also covers associated office visits, urine drug screens, and behavioral therapy.
• Commercial insurance: Under the Mental Health Parity and Addiction Equity Act (MHPAEA) and the Affordable Care Act (ACA), most commercial insurance plans must cover MAT for substance use disorders on par with other medical conditions.
• Patient assistance programs: The manufacturers of Suboxone and Sublocade offer patient assistance programs for uninsured or underinsured individuals.
• Generic buprenorphine/naloxone: Generic formulations are substantially less expensive than brand-name Suboxone and are equally effective.
• State-funded programs: NJ provides funding for substance use disorder treatment for individuals without insurance or who are underinsured.

Online Suboxone Treatment: What to Know

Telehealth MAT Regulations

The COVID-19 pandemic prompted regulatory changes that dramatically expanded telehealth access for MAT:

• DEA flexibilities: Temporary pandemic-era rules allowed buprenorphine prescribing via telehealth without an in-person evaluation. As of 2025, the DEA has made provisions to continue some telehealth flexibilities for established patients.
• State-level telehealth laws: New Jersey permits telehealth prescribing of buprenorphine, though regulations continue to evolve. Patients should confirm that their provider is licensed in New Jersey.
• Insurance coverage: NJ Medicaid and most commercial insurers cover telehealth MAT visits at the same rate as in-person visits.

Choosing a Legitimate Provider

The expansion of telehealth MAT has created new access opportunities but also new concerns. When evaluating online Suboxone providers:

Indicators of a legitimate telehealth MAT provider:

• Licensed in New Jersey and verifiable through the NJ Board of Medical Examiners
• Conducts a thorough initial assessment including substance use history, medical history, and mental health screening
• Uses structured treatment protocols with regular follow-up appointments
• Provides or coordinates behavioral therapy in addition to medication
• Conducts urine drug screening (some telehealth programs use mail-in test kits)
• Is transparent about costs, insurance acceptance, and what the program includes

Warning signs of a problematic provider:

• No initial assessment or a perfunctory one
• “Pill mill” approach — large doses prescribed without clinical justification
• No follow-up or monitoring plan
• Cash-only payment with no insurance billing option
• Pressure to purchase medication through a specific pharmacy
• No coordination with other treatment services

Telehealth MAT represents a genuine advance in treatment access, particularly for individuals in rural areas, those with transportation limitations, or those whose work schedules make in-person visits difficult. When provided by legitimate, licensed clinicians, telehealth Suboxone treatment produces outcomes comparable to in-person care.

---

This article is part of our complete guide to opioid addiction in New Jersey. For information on withdrawal management, see opioid withdrawal medications and treatment. For perspectives on alternative approaches, visit kratom and opioid addiction.

For comparisons of MAT medications, see our glossary entry on Vivitrol vs. Suboxone vs. Sublocade. For insurance coverage information, visit does insurance cover rehab?.